Milan: DiaSorin in the red - Borsa Italiana
DIASORIN S.p.A. REPORT ON THE REMUNERATION POLICY AND FEES PAID 2020
DiaSorin S.p.A. (DSRL.F) Company Information - Simply Wall St
Annual Financial Report
/cloudfront-us-east-2.images.arcpublishing.com/reuters/34L6IFUZ2JLLDHCVNW34Y664HE.jpg "Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year | Reuters")
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year | Reuters
DiaSorin's LIAISON® SARS-CoV-2 Diagnostic Solutions | DiaSorin
DiaSorin Molecular LLC | LinkedIn
DiaSorin Inc. | DiaSorin
Results | DiaSorin
DiaSorin | Saluggia
DiaSorin | Saluggia
Minnesota State College Southeast - News, Events, and Updates
DiaSorin - The Diagnostic Specialist
Annual Financial Report
Borsa: Milano frena ancora (-1,1%), pesano Diasorin e Stellantis - Notizie - Ansa.it
Report on the Remuneration Policy
DiaSorin Italia S.p.A. | DiaSorin
DiaSorin | LinkedIn
DiaSorin Molecular LLC | LinkedIn
LIAISON® XL | DiaSorin
DiaSorin to Acquire Focus Diagnostics Unit for $300 Million | Clinical Lab Products
Press Release
DiaSorin announces the launch of a fully automated serology test to detect antibodies against SARS-CoV-
DiaSorin Molecular Receives FDA Clearance for Reliable C. difficile Assay on LIAISON MDX Platform | Technology Networks
DiaSorin | Saluggia
DiaSorin : Incorporating medium-term hiccups; but re-rating potential remains intact
Homepage - DiaSorin Molecular
REPORT ON THE REMUNERATION POLICY FOR THE YEAR 2022 AND REMUNERATION PAID IN THE YEAR 2021 OF DIASORIN S.p.A.
LIAISON® XL | DiaSorin
Borsa: Milano recupera (-0,5%) con Mps, male Cnh e Diasorin - Notizie - Ansa.it
DiaSorin: Overvalued Italian Healthcare Company (OTCMKTS:DSRLF) | Seeking Alpha
DiaSorin | Saluggia
DiaSorin S.p.A. : Shareholders Board Members Managers and Company Profile | IT0003492391 | MarketScreener
Diasorin heads to the US with $1.8bn Luminex deal | Evaluate
Annual Financial Report
DiaSorin Molecular LLC | LinkedIn
DiaSorin - The Diagnostic Specialist
Annual Financial Report
COVID-19 | Updates | DiaSorin
Shares in Diasorin surge ahead of coronavirus diagnostic test launch
DiaSorin | Saluggia
DiaSorin concludes acquisition of Luminex for $1.8bn
DiaSorin : Taking on board the near-term difficulties -August 16, 2023 at 05:46 am| MarketScreener
Italian test maker DiaSorin puts down $1.8B for Luminex in diagnostics tie-up | Fierce Biotech
DiaSorin Spa Italy - DiaSorin Molecular
proudtobeDiaSorin | DiaSorin
DiaSorin - The Diagnostic Specialist
Results | DiaSorin
Diasorin, il titolo vola in borsa dopo i conti del primo semestre: utili e ricavi in calo ma sopra le attese - MilanoFinanza News
MeMed partners with Italy's DiaSorin to commercialize bacteria vs virus test | The Times of Israel
DiaSorin | Saluggia
DiaSorin
